NYCM was found to co-immunoprecipitate with MYCN and kinase GSK3B, which natively phosphorylates MYCN to target it to the proteasome for degradation (Sjostrom et al. 2005), in both neuroblastoma (Suenaga 2014) and bladder cancer lines (Zhu et al. 2018). This evidence concerns the gene GSK3B and urinary bladder cancer.